My Nonprofit Reviews

Sergio Q. - charity reviews, charity ratings, best charities, best nonprofits, search nonprofits

Sergio Q.

94 profile views
1 reviews

Review for Cancer Research Institute, Inc., New York, NY, USA

Rating: 5 stars  

the Cancer Research Institute not only funded my postdoctoral research in tumor immunology but inserted me into the perfect environment to start building my research career. Through their PhD, postdoctoral and new investigator awards programs plus their anual meetings, the CRI puts together an impressive group of scientists all with different expertises and ideas but at the same time all with the same general goal: to defeat cancer.

The caliber of the scientists involved in CRI is simply outstanding, and the fact that many times a year they are all put together in the same room to discuss failures and successes in our fight against cancer has definitively yielded promising results. This is the perfect environment to be inserted as a young investigator and I am really grateful to have had the opportunity to be part of this group of scientist. Most importantly, the network of scientists generated under CRI's umbrella is a permanent one, as investigators continue to interact and collaborate in cancer related projects for much longer than their CRI sponsored funding.

CRI is much more than a charity or funding agency, is truly an incubator for fantastic science, research and development.

How does this organization compare with others in the same sector?

Very Well

How much of an impact do you think this organization has?

Life-changing

Will you recommend this organization to others?

Definitely

What is unique about this organization?

the caliber of the scientists, and the long term vision that this organization has regarding the generation of the perfect critical mass of scientist working in immunology and cancer.

When was your last experience with this nonprofit?

2011

Role:  Professional with expertise in this field & CRI funded my postdoctoral research in which I investigated how the immune response to cancer is inhibited and how an antibody to one inhibitory receptor on T cells, called CTLA-4, can promote tumor rejection. CTLA-4, also know as Ipilimumab is now an FD.